News coverage about Regenxbio (NASDAQ:RGNX) has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Regenxbio earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.833285742134 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Regenxbio (RGNX) Price Target Raised to $85.00 at Chardan Capital (americanbankingnews.com)
- Regenxbio (RGNX) Stock Rating Lowered by BidaskClub (americanbankingnews.com)
- Regenxbio Inc (RGNX) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- Regenxbio Inc (RGNX) CFO Sells $150,000.00 in Stock (americanbankingnews.com)
A number of analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Regenxbio from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a report on Thursday, March 8th. Raymond James Financial reaffirmed a “buy” rating on shares of Regenxbio in a report on Friday, January 5th. Morgan Stanley dropped their price target on shares of Regenxbio from $36.00 to $35.00 and set an “overweight” rating on the stock in a report on Wednesday, March 14th. BidaskClub cut shares of Regenxbio from a “buy” rating to a “hold” rating in a research note on Tuesday, March 13th. Finally, Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a research note on Monday, December 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $40.63.
Regenxbio (NASDAQ:RGNX) last issued its quarterly earnings data on Tuesday, March 6th. The biotechnology company reported ($0.51) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.20. Regenxbio had a negative net margin of 704.02% and a negative return on equity of 36.48%. The firm had revenue of $2.04 million for the quarter. research analysts expect that Regenxbio will post -2.44 earnings per share for the current fiscal year.
In other Regenxbio news, insider Kenneth T. Mills sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $26.56, for a total transaction of $265,600.00. Following the sale, the insider now owns 238,530 shares in the company, valued at approximately $6,335,356.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Vittal Vasista sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $30.16, for a total transaction of $150,800.00. The disclosure for this sale can be found here. Insiders sold a total of 65,000 shares of company stock worth $1,960,200 in the last quarter. Company insiders own 17.00% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.wkrb13.com/2018/04/01/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-regenxbio-rgnx-share-price.html.
Regenxbio Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.